RESEARCH TRIANGLE PARK, N.C., Oct. 9, 2008 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) announced today the start of a Phase II proof-of-concept clinical trial to evaluate the safety and efficacy of senicapoc, the Company's novel orally available small molecule inhibitor of the KCa3.1 potassium ion channel, in patients with allergic asthma. Results from a preclinical study demonstrated the ability of senicapoc to reverse antigen-induced increases in airway resistance and airway hyper-reactivity. The objective of the current trial is to confirm these positive results in a clinical setting. This Phase II trial is a double-blind, placebo-controlled, parallel group study that is designed to assess the safety and efficacy of senicapoc, administered once a day for two weeks, on pulmonary function in patients with allergic asthma...
[read full story]
Your Web Site
